Epigenomic and transcriptomic approaches in the post-genomic era

Path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart

Cinzia Perrino, Albert Laszló Barabási, Gianluigi Condorelli, Sean Michael Davidson, Leon De Windt, Stefanie Dimmeler, Felix Benedikt Engel, Derek John Hausenloy, Joseph A Hill, Linda Wilhelmina Van Laake, Sandrine Lecour, Jonathan Leor, Rosalinda Madonna, Manuel Mayr, Fabrice Prunier, Joost Petrus Geradus Sluijter, Rainer Schulz, Thomas Thum, Kirsti Ytrehus, Péter Ferdinandy

Research output: Contribution to journalReview article

37 Citations (Scopus)

Abstract

Despite advances in myocardial reperfusion therapies, acute myocardial ischaemia/reperfusion injury and consequent ischaemic heart failure represent the number one cause of morbidity and mortality in industrialized societies. Although different therapeutic interventions have been shown beneficial in preclinical settings, an effective cardioprotective or regenerative therapy has yet to be successfully introduced in the clinical arena. Given the complex pathophysiology of the ischaemic heart, large scale, unbiased, global approaches capable of identifying multiple branches of the signalling networks activated in the ischaemic/reperfused heart might be more successful in the search for novel diagnostic or therapeutic targets. High-throughput techniques allow high-resolution, genome-wide investigation of genetic variants, epigenetic modifications, and associated gene expression profiles. Platforms such as proteomics and metabolomics (not described here in detail) also offer simultaneous readouts of hundreds of proteins and metabolites. Isolated omics analyses usually provide Big Data requiring large data storage, advanced computational resources and complex bioinformatics tools. The possibility of integrating different omics approaches gives new hope to better understand the molecular circuitry activated by myocardial ischaemia, putting it in the context of the human ‘diseasome’. Since modifications of cardiac gene expression have been consistently linked to pathophysiology of the ischaemic heart, the integration of epigenomic and transcriptomic data seems a promising approach to identify crucial disease networks. Thus, the scope of this Position Paper will be to highlight potentials and limitations of these approaches, and to provide recommendations to optimize the search for novel diagnostic or therapeutic targets for acute ischaemia/reperfusion injury and ischaemic heart failure in the post-genomic era.

Original languageEnglish (US)
Pages (from-to)725-736
Number of pages12
JournalCardiovascular Research
Volume113
Issue number7
DOIs
StatePublished - 2017

Fingerprint

Epigenomics
Cell Biology
Reperfusion Injury
Myocardial Ischemia
Heart Failure
Myocardial Reperfusion Injury
Therapeutics
Myocardial Reperfusion
Metabolomics
Information Storage and Retrieval
Computational Biology
Transcriptome
Proteomics
Genome
Morbidity
Gene Expression
Mortality
Proteins

Keywords

  • Big Data
  • Bioinformatics
  • Multiomics
  • Network analysis
  • Omics
  • Tailored medicine

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Epigenomic and transcriptomic approaches in the post-genomic era : Path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. / Perrino, Cinzia; Barabási, Albert Laszló; Condorelli, Gianluigi; Davidson, Sean Michael; De Windt, Leon; Dimmeler, Stefanie; Engel, Felix Benedikt; Hausenloy, Derek John; Hill, Joseph A; Van Laake, Linda Wilhelmina; Lecour, Sandrine; Leor, Jonathan; Madonna, Rosalinda; Mayr, Manuel; Prunier, Fabrice; Sluijter, Joost Petrus Geradus; Schulz, Rainer; Thum, Thomas; Ytrehus, Kirsti; Ferdinandy, Péter.

In: Cardiovascular Research, Vol. 113, No. 7, 2017, p. 725-736.

Research output: Contribution to journalReview article

Perrino, C, Barabási, AL, Condorelli, G, Davidson, SM, De Windt, L, Dimmeler, S, Engel, FB, Hausenloy, DJ, Hill, JA, Van Laake, LW, Lecour, S, Leor, J, Madonna, R, Mayr, M, Prunier, F, Sluijter, JPG, Schulz, R, Thum, T, Ytrehus, K & Ferdinandy, P 2017, 'Epigenomic and transcriptomic approaches in the post-genomic era: Path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart', Cardiovascular Research, vol. 113, no. 7, pp. 725-736. https://doi.org/10.1093/cvr/cvx070
Perrino, Cinzia ; Barabási, Albert Laszló ; Condorelli, Gianluigi ; Davidson, Sean Michael ; De Windt, Leon ; Dimmeler, Stefanie ; Engel, Felix Benedikt ; Hausenloy, Derek John ; Hill, Joseph A ; Van Laake, Linda Wilhelmina ; Lecour, Sandrine ; Leor, Jonathan ; Madonna, Rosalinda ; Mayr, Manuel ; Prunier, Fabrice ; Sluijter, Joost Petrus Geradus ; Schulz, Rainer ; Thum, Thomas ; Ytrehus, Kirsti ; Ferdinandy, Péter. / Epigenomic and transcriptomic approaches in the post-genomic era : Path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. In: Cardiovascular Research. 2017 ; Vol. 113, No. 7. pp. 725-736.
@article{68d8a90e55aa47ca9914b902a47b5ee6,
title = "Epigenomic and transcriptomic approaches in the post-genomic era: Path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart",
abstract = "Despite advances in myocardial reperfusion therapies, acute myocardial ischaemia/reperfusion injury and consequent ischaemic heart failure represent the number one cause of morbidity and mortality in industrialized societies. Although different therapeutic interventions have been shown beneficial in preclinical settings, an effective cardioprotective or regenerative therapy has yet to be successfully introduced in the clinical arena. Given the complex pathophysiology of the ischaemic heart, large scale, unbiased, global approaches capable of identifying multiple branches of the signalling networks activated in the ischaemic/reperfused heart might be more successful in the search for novel diagnostic or therapeutic targets. High-throughput techniques allow high-resolution, genome-wide investigation of genetic variants, epigenetic modifications, and associated gene expression profiles. Platforms such as proteomics and metabolomics (not described here in detail) also offer simultaneous readouts of hundreds of proteins and metabolites. Isolated omics analyses usually provide Big Data requiring large data storage, advanced computational resources and complex bioinformatics tools. The possibility of integrating different omics approaches gives new hope to better understand the molecular circuitry activated by myocardial ischaemia, putting it in the context of the human ‘diseasome’. Since modifications of cardiac gene expression have been consistently linked to pathophysiology of the ischaemic heart, the integration of epigenomic and transcriptomic data seems a promising approach to identify crucial disease networks. Thus, the scope of this Position Paper will be to highlight potentials and limitations of these approaches, and to provide recommendations to optimize the search for novel diagnostic or therapeutic targets for acute ischaemia/reperfusion injury and ischaemic heart failure in the post-genomic era.",
keywords = "Big Data, Bioinformatics, Multiomics, Network analysis, Omics, Tailored medicine",
author = "Cinzia Perrino and Barab{\'a}si, {Albert Laszl{\'o}} and Gianluigi Condorelli and Davidson, {Sean Michael} and {De Windt}, Leon and Stefanie Dimmeler and Engel, {Felix Benedikt} and Hausenloy, {Derek John} and Hill, {Joseph A} and {Van Laake}, {Linda Wilhelmina} and Sandrine Lecour and Jonathan Leor and Rosalinda Madonna and Manuel Mayr and Fabrice Prunier and Sluijter, {Joost Petrus Geradus} and Rainer Schulz and Thomas Thum and Kirsti Ytrehus and P{\'e}ter Ferdinandy",
year = "2017",
doi = "10.1093/cvr/cvx070",
language = "English (US)",
volume = "113",
pages = "725--736",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Epigenomic and transcriptomic approaches in the post-genomic era

T2 - Path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart

AU - Perrino, Cinzia

AU - Barabási, Albert Laszló

AU - Condorelli, Gianluigi

AU - Davidson, Sean Michael

AU - De Windt, Leon

AU - Dimmeler, Stefanie

AU - Engel, Felix Benedikt

AU - Hausenloy, Derek John

AU - Hill, Joseph A

AU - Van Laake, Linda Wilhelmina

AU - Lecour, Sandrine

AU - Leor, Jonathan

AU - Madonna, Rosalinda

AU - Mayr, Manuel

AU - Prunier, Fabrice

AU - Sluijter, Joost Petrus Geradus

AU - Schulz, Rainer

AU - Thum, Thomas

AU - Ytrehus, Kirsti

AU - Ferdinandy, Péter

PY - 2017

Y1 - 2017

N2 - Despite advances in myocardial reperfusion therapies, acute myocardial ischaemia/reperfusion injury and consequent ischaemic heart failure represent the number one cause of morbidity and mortality in industrialized societies. Although different therapeutic interventions have been shown beneficial in preclinical settings, an effective cardioprotective or regenerative therapy has yet to be successfully introduced in the clinical arena. Given the complex pathophysiology of the ischaemic heart, large scale, unbiased, global approaches capable of identifying multiple branches of the signalling networks activated in the ischaemic/reperfused heart might be more successful in the search for novel diagnostic or therapeutic targets. High-throughput techniques allow high-resolution, genome-wide investigation of genetic variants, epigenetic modifications, and associated gene expression profiles. Platforms such as proteomics and metabolomics (not described here in detail) also offer simultaneous readouts of hundreds of proteins and metabolites. Isolated omics analyses usually provide Big Data requiring large data storage, advanced computational resources and complex bioinformatics tools. The possibility of integrating different omics approaches gives new hope to better understand the molecular circuitry activated by myocardial ischaemia, putting it in the context of the human ‘diseasome’. Since modifications of cardiac gene expression have been consistently linked to pathophysiology of the ischaemic heart, the integration of epigenomic and transcriptomic data seems a promising approach to identify crucial disease networks. Thus, the scope of this Position Paper will be to highlight potentials and limitations of these approaches, and to provide recommendations to optimize the search for novel diagnostic or therapeutic targets for acute ischaemia/reperfusion injury and ischaemic heart failure in the post-genomic era.

AB - Despite advances in myocardial reperfusion therapies, acute myocardial ischaemia/reperfusion injury and consequent ischaemic heart failure represent the number one cause of morbidity and mortality in industrialized societies. Although different therapeutic interventions have been shown beneficial in preclinical settings, an effective cardioprotective or regenerative therapy has yet to be successfully introduced in the clinical arena. Given the complex pathophysiology of the ischaemic heart, large scale, unbiased, global approaches capable of identifying multiple branches of the signalling networks activated in the ischaemic/reperfused heart might be more successful in the search for novel diagnostic or therapeutic targets. High-throughput techniques allow high-resolution, genome-wide investigation of genetic variants, epigenetic modifications, and associated gene expression profiles. Platforms such as proteomics and metabolomics (not described here in detail) also offer simultaneous readouts of hundreds of proteins and metabolites. Isolated omics analyses usually provide Big Data requiring large data storage, advanced computational resources and complex bioinformatics tools. The possibility of integrating different omics approaches gives new hope to better understand the molecular circuitry activated by myocardial ischaemia, putting it in the context of the human ‘diseasome’. Since modifications of cardiac gene expression have been consistently linked to pathophysiology of the ischaemic heart, the integration of epigenomic and transcriptomic data seems a promising approach to identify crucial disease networks. Thus, the scope of this Position Paper will be to highlight potentials and limitations of these approaches, and to provide recommendations to optimize the search for novel diagnostic or therapeutic targets for acute ischaemia/reperfusion injury and ischaemic heart failure in the post-genomic era.

KW - Big Data

KW - Bioinformatics

KW - Multiomics

KW - Network analysis

KW - Omics

KW - Tailored medicine

UR - http://www.scopus.com/inward/record.url?scp=85027102298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027102298&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvx070

DO - 10.1093/cvr/cvx070

M3 - Review article

VL - 113

SP - 725

EP - 736

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 7

ER -